48,466
edits
Line 32: | Line 32: | ||
===Protocol notes=== | ===Protocol notes=== | ||
*High-grade [[gallbladder dysplasia|dysplasia]] ''should'' prompt submitting the gallbladder in total, if cancer is not present.<ref name=uscap2017_akki/> | |||
*[[Intestinal metaplasia of the gallbladder]] does ''not'' have to be [[submitted in total]].<ref name=uscap2017_akki>Akki ''et al.'' (2017) "Detecting Incidental Gallbladder Adenocarcinoma: When to Submit the Entire Gallbladder". Available at: [http://www.abstracts2view.com/uscap17/view.php?nu=USCAP17L_2016 http://www.abstracts2view.com/uscap17/view.php?nu=USCAP17L_2016]. United States and Canadian Academy of Pathology Annual Meeting. Accessed on: April 9, 2017.</ref> | *[[Intestinal metaplasia of the gallbladder]] does ''not'' have to be [[submitted in total]].<ref name=uscap2017_akki>Akki ''et al.'' (2017) "Detecting Incidental Gallbladder Adenocarcinoma: When to Submit the Entire Gallbladder". Available at: [http://www.abstracts2view.com/uscap17/view.php?nu=USCAP17L_2016 http://www.abstracts2view.com/uscap17/view.php?nu=USCAP17L_2016]. United States and Canadian Academy of Pathology Annual Meeting. Accessed on: April 9, 2017.</ref> | ||
====Staging==== | ====Staging==== | ||
===Alternate approaches=== | ===Alternate approaches=== |
edits